Optimizing treatment in homozygous familial hypercholesterolemia: Monocentric observational clinical study on efficacy and safety of evinacumab and lomitapide combination
Journal of Clinical Lipidology · 2026
DOI: 10.1016/j.jacl.2026.03.014 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Marta Biolo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Benzimidazoles, Antibodies, Monoclonal, Humanized, Homozygous Familial Hypercholesterolemia, Anticholesteremic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Genetic variants of the low-density lipoprotein (LDL) receptor cause homozygous familial hypercholesterolemia (HoFH). Disease-specific treatment options include lipoprotein apheresis and lomitapide, and more recently, the angiopoietin-like 3 (ANGPTL3)-targeting monoclonal antibody evinacumab. OBJECTIVE: We evaluated the efficacy and safety of this therapeutic combination in patients with HoFH. METHODS: We report a single-center, real-world clinical experience including 6 patients with HoFH, 4 of whom were pediatric, with persistently elevated LDL-cholesterol (LDL-C) (>130 mg/dL), despite optimized lipid-lowering therapy, including lipoprotein apheresis and lomitapide. These patients received intravenous evinacumab at 15 mg/kg every 4 weeks on top of stable background lipid-lowering therapy, including lomitapide, and after discontinuation of lipoprotein apheresis. RESULTS: At baseline, immediately before evinacumab initiation, mean LDL-C was 289.6 ± 80.6 mg/dL (7.25 ± 2.08 mmol/L). Treatment with evinacumab resulted in a sustained reduction in LDL-C by 55.0% ± 12.5% through week 48. In addition, evinacumab reduced apolipoprotein B (ApoB) by 46.0% ± 10.5%, total cholesterol by 53.1% ± 11.4%, and triglycerides by 51.9% ± 8.2%. Plasma ANGPTL3 levels approximately doubled, whereas proprotein convertase subtilisin/kexin type 9 decreased modestly, reaching a -15% at week 24. The combination of evinacumab and lomitapide was generally well tolerated throughout the study period with no serious treatment-emergent adverse events. One patient experienced a delayed infusion reaction, and another a transient headache and flu-like symptoms. CONCLUSION: Evinacumab added to lomitapide-based background lipid-lowering therapy was associated with marked reductions in LDL-C, ApoB, and other lipid parameters, with a favorable safety profile. These findings support the potential clinical usefulness of the evinacumab/lomitapide combination in both pediatric and adult patients with HoFH, although decisions regarding lipoprotein apheresis should remain individualized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Padova, Padova, Italy.
- Department of Medicine, University of Padova, Padova, Italy. Electronic address: nicola.ferri@unipd.it.
Zitieren
APA
Biolo, M., Lupo, M. G., Marodin, G., Portinari, C., Zambon, A., Bertocco, S., Previato, L., Simioni, P., Ferri, N., & Zambon, S. (2026). Optimizing treatment in homozygous familial hypercholesterolemia: Monocentric observational clinical study on efficacy and safety of evinacumab and lomitapide combination. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.03.014
Vancouver
Biolo M, Lupo MG, Marodin G, Portinari C, Zambon A, Bertocco S, et al. Optimizing treatment in homozygous familial hypercholesterolemia: Monocentric observational clinical study on efficacy and safety of evinacumab and lomitapide combination. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2026.03.014
BibTeX
@article{Biolo2026,
author = {Biolo, Marta and Lupo, Maria Giovanna and Marodin, Giorgia and Portinari, Camilla and Zambon, Alberto and Bertocco, Sandra and Previato, Lorenzo and Simioni, Paolo and Ferri, Nicola and Zambon, Sabina},
title = {Optimizing treatment in homozygous familial hypercholesterolemia: Monocentric observational clinical study on efficacy and safety of evinacumab and lomitapide combination},
journal = {Journal of Clinical Lipidology},
year = {2026},
doi = {10.1016/j.jacl.2026.03.014}
}
EUVIMED